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326Reduced-Intensity Allogeneic Hematopoietic Stem
Cell Transplantation in Metastatic Colorectal Cancer
as a Novel Adoptive Cell Therapy Approach. The
European Group for Blood and Marrow
Transplantation Experience
Massimo Aglietta,1 Lisbeth Barkholt,2 Fabrizio Carnevale Schianca,1 Daniela Caravelli,1
Brigitta Omazic,2 Coludia Minotto,3 Francesco Leone,1 Patrik Hentschke,2
Giovanni Bertoldero,3 Antonio Capaldi,1 Giovannino Ciccone,4 Dietger Niederwieser,5
Olle Ringden,2 Tanner Demirer6 On behalf of the EBMT Solid Tumor Working PartyReduced-intensity conditioning (RIC) regimens for allogeneic hematopoietic stem cell transplantation (HCT)
allowed the existence of an allogeneic cell-mediated antitumor effect in metastatic colorectal cancer (mCRC)
to be explored. We report on 39 patients with progressing mCRC treated with different RIC regimens in
a multicenter clinical trial of the European Bone Marrow Transplantation Group. Disease status at transplant
was progressive disease (PD) in 31 patients (80%), stable disease (SD) in 6 (15%), and partial response (PR) in
2 (5%). All patients engrafted (median donor T cell chimerism of 90% at day 160). Transplant-related mor-
bidities were limited. Grades II-IV acute graft-versus-host disease (aGVHD) occurred in 14 patients (35%)
and chronic GVHD (cGVHD) in 9 patients (23%). Transplant-related mortality occurred in 4 patients
(10%). The best tumor responses were: 1 complete response (CR) (2%), 7 PR (18 %), and 10 SD (26%), giving
an overall disease control in 18 of 39 patients (46%). Allogeneic HCT after RIC is feasible; the collected
results compared favorably in terms of tumor response with those observed using conventional approaches
beyond second-line therapies. The study of an allogeneic cell based therapy in less advanced patients is
warranted.
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Metastatic Colorectal Cancer (mCRC) is an incur-
able disease [1]. For patients inoperable at diagnosis or
relapsing after surgery, the best available treatment is
represented by oxaliplatin or by irinotecan in combi-
nation with fluorouracil and folinic acid [2]. These
treatments, used as first-line procedures, give
a response rate of 55% to 60%, with a median time
to progression (TTP) of 7 to 10 months and a median
survival of 18 to 22 months. Once resistance to these
agents has developed, second-line chemotherapy
offers a low overall response rate (4% to 15%), with
a median TTP of 3 to 7 months and a median survival
of 9 to 12 months [3]. Molecular targeted therapies
have recently been introduced in the treatment of
mCRC. Their association with chemotherapy further
improved remission rates and survival but, in resistant
disease, their impact remains limited and no long-
lasting remissions have been reported [4-8].
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the management of mCRC.
Although first-generation clinical trials of adoptive
or vaccine therapy reported only limited success, based
on growing knowledge on the immune system and T
cell biology, there is a renewed interest to explore im-
munotherapy as a novel therapeutic strategy in CRC
[9-11]. In the context of adoptive cell-based therapy,
allogeneic hematopoietic stem cell transplantation
(HCT) represents a promising approach that may
help in overcoming some of the limitations of the
previous experiences [12].
The introduction of allogeneic HCT was founded
on the principles of maximal tumor cytoreduction and
adequate immunosuppression to permit engraftment
of HLA-identical donor stem cells. Evidence has
accumulated over the last 2 decades that the donor
stem cells may exert not only a repopulating role but
also, through the lymphocytes, a graft-versus-tumor
effect (GVT) [13]. Thus, many efforts have been
made to transform allogeneicHCT from a chemother-
apy- to an immunotherapy-based approach. Allogeneic
HCT after reduced-intensity conditioning (RIC)
accomplished this new concept [14-17]. The lower tox-
icity of the procedure allowed not only to proceed with
success with allogeneic transplantation as an up-front
treatment in selected malignancies but also to explore
the existence of alloreactivity in metastatic solid
tumors [18-22]. These diseases are often diagnosed in
elderly patients and their growth kinetic is sometimes
slow, allowing the development of a GVT effect. In
metastatic CRC, early clinical experiences demon-
strated the feasibility of the approach, giving immuno-
logic evidence of a graft-versus-CRC effect [23,24].
To better understand the potential role of RIC and
allogeneic HCT in the treatment of mCRC and to
better select candidates for second-generation studies,
we collected and analyzed the clinical data of patients
with resistant/refractory mCRC transplanted and
reported to the European Group for Blood and
Marrow Transplantation (EBMT).PATIENTS AND METHODS
Wereviewed the data of 39 patientswithmCRCwho
were treated with RIC and allogeneic HCT between
1999 and 2004 at 9 EBMT centers accordingly to a mul-
ticenter trial (http://www.ebmt.org/ClinicalTrials/Trial-
s.aspx then select STWP-02) that allowed 5 different
RICs. Some of these patients have been already described
in single institution reports [24,25]. Patients were
required to have a disease that could be evaluated radio-
graphically and to have an HLA-identical donor or
a matched unrelated donor (URD) typed by allele level
polymerase chain reaction (PCR) single-stranded poly-
morphism, andwhowas at least A, B, andDRb1 compat-
ible with the recipient. At each center, all patients anddonors had to sign a written informed consent, and the
protocol was approved by theLocal Ethical Committees.
Patients were treated according to different regimens for
reduced-intensity HCT (Table 2). The conditioning
regimenswere total-body irradiation (TBI) 2Gy/Fludar-
abine (25 mg/mg days –3, –2, and –1), Cyclophospha-
myde (30 mg/kg/day days –4 and –3)/Fludarabine (30
mg/mEq days –4 and –3), Thiotepa (5 mg/kg day –5)/
Cyclophosphamyde (30 mg/kg/day days –4 and –3)/Flu-
darabine (30mg/mEqdays –4 and–3), Busulfan (4mg/kg
days –8 and –7)/Fludarabine (30mg/mEqdays –8, –7, –6,
–5, –4, and –3) in 22, 15, 1, and 1 patients, respectively.
To prevent graft rejection and graft-versus-host
disease (GVHD), post transplant immunosuppres-
sion consisted of the combination of cyclosporine
(CSA) and mycophenolate mofetil (MMF) in TBI-
based regimens and of the combination of CSA and
methotrexate (MTX) short course in all the others;
in 5 patients (4 unrelated, 1 related) as GVHD pro-
phylaxis antithymocyte globulin (ATG) was also
added at a dose of 1.5 mg/kg for 4 days before trans-
plant.
In TBI regimens, CSA was started on day –3 and
given at a dose of 6 mg/kg (oral) or 1.5 mg/kg (intrave-
nously) every 12 hours. CSA levels were targeted at the
upper therapeutic ranges (500 ng/L as defined by the
fluorescence polarization method by Abbott TDX,
Abbott Park, IL) in the first 28 days, maintained in
normal ranges until day 156, and then tapered at
25% per week to be discontinued on day 190. MMF
was started at a dose of 15 mg/kg (oral) every 12 hours
on day 0 and stopped without tapering on day 127.
In the other regimens CSA (target blood levels,
150-300 ng/mL) and short-course methotrexate
(MTX; 10 mg/msq day 1; 8 mg/msq days 3 and 6)
were used; CSA was started on day –3, maintained in
normal ranges until day 156, and then tapered at
25% per week to be discontinued on day 190. Taper-
ing schedules were modified if GVHD developed and
according to the disease status. All patients but 1 who
was a 1 antigenmismatch were grafted withHLA iden-
tical sibling donors matched for classes I and II (A, B,
C, DRb1) with high-resolution molecular typing [26].
Patients transplanted using URD had 6 of 6 HLA loci
in common.Donors were given 16 mg/kg daily of gran-
ulocyte-colony stimulating factor (G-CSF) subcutane-
ously for 4 to 5 days, after which peripheral blood stem
cells were collected. After transplant, all patients
received prophylaxis against bacterial, viral, fungal,
and Pneumocystis carinii infection according to previ-
ously published protocols [27-30].Chimerism, Treatment-Related Toxicities,
GVHD, and Donor Lymphocyte Infusions
The degree of donor chimerism was assessed at
days 130, 160, 190, 1180, and 1360 after
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CD 131 or CD 331 myeloid cells, as well as in some
centers on bonemarrow cells accordingly to previously
published protocols. Mixed chimerism was defined as
the presence of 1% to 95% donor CD31 cells, whereas
complete chimerism was defined as .95% donor
CD31 cells [31]. Treatment-related toxicities were
graded according to the Common Toxicity Criteria
of the National Cancer Institute 2.0 (http://ctep.
cancer.gov/reporting/ctc-3.htlm). The severity of
GVHD was graded according to the modified Seattle
criteria [32]. Acute GVHD was treated with CSA if it
occurred after discontinuation. If the patient was still
on CSA, methylprednisolone i.v. or oral prednisone
1.0-2.0 mg/kg/day was started. Patients who had
progressive disease after they had discontinued immu-
nosuppression in the absence of severe GVHD (ie,
grade III-IV) were eligible for a donor leukocyte infu-
sion (DLI). T lymphocytes (CD31) were administered
in escalating doses starting with the 1  106 CD31
cells/kg, followed by 1  107 CD31 cells/kg 30 days
later and 5-10  107 CD31 cells/kg 30 days later if
no response or GVHD occurs. In 2 patients, DLI
was depleted of CD81 cells, and in another case, the
patient received infusions of CD31/CD 561 cells
according to a single institution protocol. The preoce-
dures of depletion and selection were performed by
immunomagnetic labeling of cells followed by
separation of the positive and negative fraction using
an automated system (CliniMACS).
Endpoints and Assessment of Response
The following endpoints were assessed: achieve-
ment of a status of mixed chimerism that was defined
as between 1% and 95% peripheral blood (PB) donor
CD31 cells, incidence of acute GVHD (aGVHD) and
chronic GVHD (cGHVD), treatment-related mortal-
ity (TRM) and toxicities, tumor response, overall
survival (OS), and, in responding patients, time to
treatment failure.
Tumor response was scored according to the inter-
national RECIST criteria [33]. Tumor size was
assessed by a spiral computed tomography (CT) of
the brain, chest, and abdomen at days 130, 160,
190, 1180, and 1365, or when clinically indicated.
To be considered responsive, a patient had to fulfill
criteria of tumor-size changes that define complete
response (CR), partial response (PR) or stable disease
(SD) compared to base-line CT measurement.
Statistical Analysis
Proportions were compared between groups with
Fisher’s exact test. To estimate the association
between some potential predictors of success and the
response after transplant a logistic regression model
was used. OS was estimated by the Kaplan-Meiermethod from the date of transplant until the date of
death (because of any cause). The Log-rank test was
used to compare the survival of subgroups of patients,
stratified according to some prognostic factors.
Adjusted hazard ratios (HR) and a corresponding
95% confidence interval (CI) for OS were estimated
with the Cox proportional hazards model. The cumu-
lative incidence of GVHD during the first 100 days
after transplant was estimated with the Gooley
method, taking into account mortality from any cause
as a competitive risk [34]. Analyses were conducted by
SAS 8.2 (SAS Institute, Cary, NC) and by R 2.1.0,
package ‘‘cmprsk.’’RESULTS
Patients Characteristics
The characteristics of the 39 patients are given in
Table 1. The pretransplant status was PD in 31
patients (80%), SD in 6 (15%), and PR in 2 (5%) cases.
Thirty-eight patients (97%) had been previously
treated: 23 (58%) only with chemotherapy regimens
containing 5-fluorouracil (5FU), oxaliplatin, and iri-
notecan, 15 (38%) with surgery and/or chemotherapy.
Among previously treated patients, 13 (33%) patients
were treated with 1 line, 24 (62%) with 2 or more lines
of therapy (Table 1). In regard to the 2 patients who
were nor treated before transplant, 1 was not consid-
ered eligible to chemotherapy by an oncologist
because of a severe vascular disease, and the other pa-
tient was treated only with hepatic surgery and then
referred to the transplant center by a local oncologist.Engraftment, Chimerism, and Transplant-
Related Toxicity
In 1 case, bonemarrow represented the only source
of the graft; otherwise, patients were reinfused with
donor PB stem cells. The patients received a median
of 7.65  106 (2.5-55) CD341 cells/kg and a median
of 3.86  108 (0.11-33.7) CD31 cells/kg for a total of
7.9  108 (2.4-17.6) mononucleated cells/kg. After
transplant, all patients had a hematologic recovery
with a median absolute neutrophil count nadir
(ANC) of 640 (0-15,050)/mL. The median platelet
nadir was 91,000 (4000-191,000) / mL (Table 2).
Median chimerism on CD31 cells at days 130,
160, 190, and 1180 was 70% (range: 20-90), 90%
(30-100), 90% (7-100), 99% (0-100), respectively. All
patients surviving more than 365 days (11 [28%]) had
complete chimerism. An inversion of donor chimerism
was observed in 2 patients at days 1124 and 1220.
The first patient was successfully retransplanted from
the same donor, whereas the second was treated with
2 courses of DLI but the chimerism level did not
improve and the patient later died for progressing
Table 1. Patient Characteristics
Characteristics No. %
No. of patients 39
Sex
Male 25 64
Female 14 36
Age at transplant, years
Median 55
Range 3-76
Time from
diagnosis to transplant, months
Median 16
Range 4-47
Status pretransplant
PR 2 5
SD 6 15
PD 31 80
No lines CHT pretransplant
Median 2
Range 0-4
Most frequently
used chemotherapy agents
Oxaliplatin 24 61
5-Fluoro-uracil 37 94
Irinotecan 21 53
CHT indicates chemotherapy; PR, partial response; SD, stable disease;
PD, progressive disease.
High Tumor Burden was defined by the presence of at least one of the
following conditions: (1) >5 liver metastasis with the largest more than 5
cm in diameter or a single metastasis more than 10 cm in diameter; (2)
lung metastasis >5 cm in diameter; (3) lymphoadenopathy >5 cm in
diameter; (4) peritoneal carcinosis.
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occlusive diseases were not observed. Only 2 patients
developed grade 3 nonhematologic toxicities (liver
and renal, respectively), whereas no grade 4 toxicity
was registered. Cytomegalovirus (CMV) reactivationTable 2. Characteristics of Allogeneic HCT
Characteristics N %
HLA-sibling 35 89
MUD 4 10
Conditioning regimen
Seattle 22 56
Fludara + CTX 11 28
Thymoglobuline + CTX + Fludara 4 10
Thiotepa+Fludara+CTX 1 3
Bus + Fludara + ATG 1 3
CD 34+cells infused, 10^6/g
Median 7.65
Range 2.5-55
CD 3+cells infused, 10^8/g
Median 3.8
Range 0.11-33
MNC infused, 10^8/kg
Median 7.9
Range 2.4-17.65
MUD indicates matched unrelated donors; Seattle regimen, Fludarabine
30 mg/sm on days24,23,22, +2 Gy of total body irradiation on day 0;
Fludara + CTX, Fludarabine 25 mg/sm 5 days + Cyclophosphamide 60
mg/kg; Thymoglobuline +CTX+Fludara, Thymoglobuline 2.5mg/kg/day;
Fludarabine 25mg/sm 5 days +Cyclophosphamyde 60mg/kg; Thiotepa
+ Fludara +CTX5Thiotepa 5mg/kg, Fludarabine 50mg/sm,Cyclophos-
phamide 60 mg/kg; Bus + Fludara + ATG, Busulfan 1 mg/kg/day 2 days;
Fludarabine 30 mg/mEq 6 days mg + antithymocyte globulin 2.5 mg/kg/
day  4 days; MNC, mononuclear cells.occurred in 21 (54%) patients between days 145 and
1150. All cases were successfully treated with preemp-
tive antiviral regimens.
Immunosuppression Taper, GVHD, and DLI
Immunosuppression was discontinued at a median
92 days (range: 9-447) after transplant. Immunosup-
pression tapering was started earlier than was planned
according to protocol in 14 patients (35%) because of
disease progression. Acute GVHD grades I-IV
occurred in 18 patients (46%) at a median time of 50
(10-92) days after transplant and was grade I in 5
(13%) and grade II-IV in 14 patients (35%).
The gastrointestinal system and the skin were
involved in 12 patients (31%), whereas the liver was
affected in 5 (13%) patients. Chronic GVHD that
developed in 9 patients (23%) was progressive in 5
patients, and de novo in 4. Treatingmortality as a com-
petitive risk, the estimated cumulative incidence of
aGVHD during the first 100 days after transplant
reached a probability of 51.4% (95% CI 5 34.4%;
68.4%) (Figure 1).
Sixteen patients (41%) received DLI between days
175 and 288 because of disease progression (14 cases),
disease progression with chimerism loss (1 case), and
graft rejection (1 case). The median number of DLI
in each patient was 2 (1-8). Acute GVHD after DLI
developed in 4 of 16 patients (25%). The 3 patients
who received CD 8-depleted or CD31/CD 561-
selected DLI did not experience any toxicities; the
patient who received CD31/CD 561-selected DLI
achieved PR, 1 of the 2 patients reinfused with CD
8-depleted had SD, whereas the other 1 progressed.
Clinical Response, Survival, and Causes of Death
Following transplantation, 1 already reported [35]
patient (2%), experienced CR, 7 (18%) had PR, 10
(26%) had SD, giving a total of disease control in
46% of the cohort. In the responding patients, the
median time to response onset was 190 (30-365)
days, and the median time to treatment failure was
150 (60-335) days. Response was achieved either by
patients in PD (n 5 31) or by patients with disease
control (n 5 8) at transplant; precisely, compared to
pretransplant disease status, 13 of 39 patients showed
an improvement of their disease after transplant, 23
were stable, and 3 worsened (Table 3).
In regard to the chimerism status, responses were
achieved both in patients with full chimerism (9 of
17, 52%) or in patients with mixed chimerism (8 of
17, 48%); in all but 2 of mixed-chimera patients, tumor
responses were preceded by the achievement of a high
percentage of donor chimerism (80%-90%). As far as
the conditioning regimen used is concerned, responses
were observed in 9 of 17 (52%) patients transplanted
with a TBI-based regimen and in 8 of 17 (48%) patients
0.0
0.2
0.4
0.6
0.8
1.0
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Time (days)
Figure 1. Cumulative incidence of aGVHD. Cumulative incidence
(with 95% confidence bounds) of aGVHD during the first 100 days after
transplant (estimated with the Gooley method, accounting for mortality
as a competing risk).
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regimen. The median time for onset of response was
90 days (48-209) and 120 days (30-365), respectively.
Of the patients treated with DLI, 4 of 16 (25%)
achieved a tumor-response (all cases PR).
In half of the responding patients (9 of 18) tumor-
response followed an initial progression; 5 patients
(1 PR and 4 SD) experienced response only tapering
immunosuppression, whereas 4 patients achieved the
response (PR) after DLI.
The results of explorative analyses on the role of
some potential prognostic factors of response after
transplant are shown in Table 5. Disease control
(CR, PR, SD) was achieved in 13 of 22 (59.1%)
patients experiencing any form of GVHD (10 with
acute and 3 with chronic) and in 5 of 17 (29.4%) of
those without GVHD (OR 5 2.62, P 5 .195). In all
the patients with aGVHD who experienced a tumor
response the onset of GVHD preceded tumor
response. A reduced number of previous lines of che-
motherapy also seems to be associated with a higher
probability of disease control, but all these results are
statistically unstable because of small numbers.
After a median overall follow-up of 202 days
(range: 6-1020), 6 patients were still alive and 33 had
died. Progression was the cause of death in 29 patients
(74%). None died of transplant-related complicationsTable 3. Disease status at transplant and response
Disease Status
at Transplant
Best Response to Transplant
CR PR SD PD Tot
PR 0 1 1 0 2
SD 0 1 3 2 6
PD 1 5 6 19 31
Tot 1 7 10 21 39
CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease.before day 1100; 4 died after day 1100. One patient
(3%) died of GVHD and 3 (7%) of infections.
A comparison of OS of patients stratified by some
potential prognostic factors (number of metastatic
sites, number of previous CHT lines, disease status
at transplant, and development of GVHD) are plotted
in Figure 2. In a Cox proportional hazard model
including all these factors, the number of previous
chemotherapy lines (1-2 versus 3 or more) was the
strongest predictor of survival (HR 5 0.49; 95%
CI 5 0.23-1.05; P 5 .066). Response after transplant,
was not included in this analysis. However, it is of
interest that the achievement of response is associated
with a better outcome showing a survival advantage for
responders (Figures 2a-f).DISCUSSION
The disease control rate (46%) achieved in this
multicenter trial, with an approach of allo-based adop-
tive cell therapy is noteworthy for resistant mCRC.
The absence of any antitumoral activity of the drugs
used in the conditioning regimens of transplants, the
delayed onset on the responses, and the high percent-
age of donor-chimerism observed in the responding
patients suggest that the responses observed are
entirely because of a cellular mechanism.
In light of these data, the present analysis confirms
the feasibility of allogeneic HCT using RIC in mCRC
and presents clinical evidence for the existence of
a graft-versus-CRC effect as a consequence of that
procedure, raising the intriguing possibility that along
with molecular therapies, an immunological allo-
based strategy may also be explored in the cure
of mCRC [24,25,35,36].
Despite these results, the interest of the oncologic
community to explore this field seems low. The 2
major criticisms substantiating this skepticism are
that morbidity related to the procedure is still high,
and that there is lack of clear clinical benefits origi-
nated by the transplant. In respect to the first criticism,
the introduction of reduced-intensity regimens led to
a significant reduction of TRM over the last 5 years
[37], and a deeper knowledge of immunologic mecha-
nisms that act in allogeneic HCTmight soon translate
in a further reduction of the TRM [37,38]. In this
setting, the Stanford group recently achieved an
impressive low incidence of aGVHD and TRM with-
out hampering the GVT effect through a conditioning
regimen based on total lymphoid irradiation. In the
near future, the introduction of new methods and
agents for the prediction, early diagnosis and treat-
ment of GVHD and infections will lead to a further
reduction of the toxicity [39-42].
As far as the second criticism is concerned, the
absence of a clear clinical benefit is mostly because of
Table 4. Patient’s post transplant outcome
ID Previous therapies
Status at
transplant
Conditioning
regimen Engrafment
Chimerism+60
CD3+
GVHD
prophylaxis GVHD grade DLI Survival
Cause
of death
1 No PD 2Gy+FLU Yes 100 CSA + MMF II No 122 Infection
2 Liver surgery PD 2Gy+FLU Yes 90 CSA + MMF II Yes 194 PD
3 Nordic FLV PD 2Gy + FLU Yes 80 CSA + MMF 0 Yes 330 PD
4 Liver surgery, RF-liver PD 2Gy+FLU Yes 100 CSA + MMF Chronic Yes 528 PD
5 Nordic FLV, CPT- 11, Ra-imm.therapy SD 2Gy+FLU Yes 90 CSA + MMF I/Chronic No 222 PD
6 Nordic FLV, CPT-11/Oxyplatin SD 2Gy+FLU Yes 30 CSA + MMF III Yes 113 Infection
7 FOLFOX, liver
surgery, RF-liver
PR CY + FLU Yes 95 CSA+MTx 0 Yes 1063 Infection
8 Liver surgery, RF-liver PD CY+FLU Yes 90 CSA + MMF I/Chronic Yes 620 PD
9 Liver surgery SD Thymo + CY +FLU Yes 100 CSA+MTx II Yes 330 PD
10 FOLFIRI SD CY+FLU Yes 95 CSA+MTx I/Chronic Yes 447
11 FOLFIRI PD CY+FLU Yes 80 CSA+MTx III Yes 376
12 FOLFIRI, FOLFOX, Xeloda PD Thymo + CY + FLU Yes 100 CSA+MTx III No 157 PD
13 FOLFIRI, oxyplatin, CPT-11/Xeloda PD Thymo + CY +FLU Yes 100 CSA+MTx 0 Yes 140 PD
14 FLV, FOLFIRI PD CY + FLU Yes 80 CSA+MTx II Yes 328
15 FOLFIRI PD Thymo + CY +FLU Yes 100 CSA+MTx I No 210
16 De Gramont, Xeloda PD CY+FLU Yes 80 CSA 0 No 30 PD
17 FOLFIRI, FOLFOX, Xeloda PD 2Gy+FLU Yes 80 CSA + MMF 0 No 44 PD
18 FOLFOX PD 2Gy+FLU Yes 97 CSA + MMF Chronic No 200 PD
19 FOLFOX PD 2Gy+FLU Yes 65 CSA + MMF 0 No 143 PD
20 FOLFOX PD 2Gy+FLU Yes 59 CSA + MMF 0 No 145 PD
21 FOLFOX, liver surgery, FOLFOX PD 2Gy+FLU Yes 74 CSA + MMF Chronic No 361 PD
22 5FU/LV, Tomudex, CPT-11 PD 2Gy+FLU Yes 70 CSA + MMF II Yes 379 PD
23 FOLFOX, Liver
surgery, FOLFIRI
PD 2Gy+FLU Yes 50 CSA + MMF 0 No 123 PD
24 FOLFOX, FOLFIRI SD 2Gy+FLU Yes 80 CSA + MMF IV No 202 GVHD
25 FOLFOX, liver surgery PD 2Gy+FLU Yes 55 CSA + MMF 0 Yes 510
26 FOLFOX, liver surgery PD 2Gy+FLU Yes 60 CSA + MMF Chronic No 227 PD
27 FOLFOX PD 2Gy+FLU Yes 52 CSA + MMF 0 Yes 330 PD
28 FOLFIRI SD 2Gy+FLU Yes 90 CSA + MMF III No 501 PD
29 Liver surgery, FOLFIRI, FOLFOX PD 2Gy+FLU Yes 50 CSA + MMF 0 No 137 PD
30 FOLFOX PD 2Gy+FLU Yes 95 CSA + MMF 0 Yes 90 PD
31 FOLFOX, CPT 11, Xeloda PD 2Gy+FLU Yes 90 CSA + MMF 0 No 609 PD
32 Liver surgery, FOLFOX, CPT 11,
Tomudex
PD 2Gy+FLU Yes 100 CSA + MMF III No 90 PD
33 LV/5FU PR BUS+FLU+ATG Yes 80 CSA II No 450 PD
34 Liver surgery, FOLFOX,
Intrahepatic CT
PD FLU+CTX Yes 50 CSA+MTx 0 No 165 PD
35 Liver surgery, LV/5FU + carboplatin,
FOLFOX, FOLFIRI
PD FLU+CTX Yes 65 CSA+MTx 0 No 285 PD
36 LV/5FU, FOLFOX, CPT 11 PD FLU+CTX Yes 70 CSA + MMF I/Chronic Yes 155 PD
37 De Gramont, FOLFOX, FOLFIRI PD FLU+CTX Yes 75 CSA+MTx 0 No 98 PD
38 Liver surgery, FOLFOX PD FLU+CTX Yes 90 CSA+Basiliximab II/Chronic No 977 PD
39 Liver surgery, 5-FU, FOLFOX,
FOLFIRI
PD THIOTEPA+FLU+CTX Yes 100 MMF+MPDN I No 143 PD
CSA indicates Cyclosporine; MMF, mycophenolate acid.
FOLFIRI5 Irinotecan 180 mg/sm; Fluorouracil 400 mg/meEq; Fluorouracil 600 mg/sm; Leucovorin 200 mg/sm; FOLFOX5Oxaliplatin 100 mg/sm; Fluo-
rouracil 400 mg/sm; Fluorouracil 600 mg/sm ; Leucovorin 200 mg/sm; De Gramont5 Fluorouracil 400 mg/sm ; Fluorouracil 600 mg/sm; Leucovorin 200
mg/sm; Tomudex 5 4 mg/sm; CPT11 5 Irinotecan 180 mg/sm.
Table 5. Association between Some Possible Prognostic
Factors and Response after Transplant*
Factors OR 95%CI P
GVDH 2.62 0.61 - 11.28 .195
Lines of previous chemotherapy
(1-2 versus >3)
3.10 0.69 - 14.03 .141
No. of metastatic sites (3-4 versus 1-2) 1.22 0.25 - 5.92 .808
Disease status at transplant
(PD versus SD or PR)
0.36 0.05 - 2.64 .318
CI indicates confidence interval; OR, odds ratio; SD, stable disease; PR,
partial response.
*Multiple logistic regression estimates, adjusted for all the variables
listed in the table.
Biol Blood Marrow Transplant 15:326-335, 2009 331GVT in Monmyeloablative HCT for Metastatic CRCthe difficulty of separating GVT from GVHD. Until
recently, our understanding of the mechanism under-
lying the GVT effect was limited, and the reaction
was extremely unpredictable and nonspecific [43].
However, at present, the possibility of generating
a specific GVT effect has been demonstrated in differ-
ent malignancies [44,45]. It has recently been shown
that in mCRC-infused donor lymphocytes not only
target metastatic sites but also that donor T cells spe-
cific to a well-characterized tumor-associated antigen
(TAA) are generated in vivo as a consequence of the
transplant procedure [25,46].
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Figure 2. OS of patients with mCRC treated with a reduced-intensity regimen and allogeneic HCT. (a) OS calculated in days from HCTof the 39 pa-
tients treated. (b) OS of patients with\3metastatic sites before HCT (n5 26 solid line) and with.3metastatic sites (n5 13, dotted line). Log rank test
P5.39890. (c) OS of patients who were transplanted after 0-1 previous lines of therapies (n5 15, solid line) and who were transplanted after 2 or more
previous lines of therapies (n5 24, dotted line). Log rank test P5.02953. (d) OS of patients who developed GVHD (n5 22, solid line) and who did not
develop aGVHD after HCT (n5 17, dotted line). Log rank test P5 .02862. (e) OS of patients who were transplanted in a status of disease progression
(n5 31, solid line), and thosewhowere transplanted in a disease control status (PR or SD; n5 8, dotted line). Log rank test P5.15666. (f) OS of patients
who had a response (n 5 18, solid line) and who had no response after HCT (n 5 21, dotted line). Log rank test P 5 .00018.
332 Biol Blood Marrow Transplant 15:326-335, 2009M. Aglietta et al.Clearly, the result of the present report, similar to
those of allogeneic HCT in renal cell carcinoma,
breast cancer, and ovarian cancer, must be taken
cautiously and do not have to be overemphasized.
The small number of patients treated, the still high
incidence of GVHD reported, and finally the low
rate (20%) of short-lasting responses are objective lim-itations of the study. However, some of these limita-
tions are not substantial for the following reasons:
first, many of the new medical strategies are based on
retrospective and small-sized studies if not directly
only on case reports [47-50]; second, the incidence of
aGVHD, far from being optimal, is similar to that
reported in other malignancies in which allogeneic
Biol Blood Marrow Transplant 15:326-335, 2009 333GVT in Monmyeloablative HCT for Metastatic CRCHCT is routinely employed [51]. Finally, as far as the
low reponse rate is concerned, many drugs (gefitinib,
erlotinib, bevacizumab, cetuximab, sorafenib) have re-
cently been considered active in different tumors even
without the achievement of a high level of tumor re-
gression using traditional Recist criteria [52-55]. If
that is true for molecular-targeted therapy, it is even
more correct for an immunologic therapy.
Thus, if the data suggest that it would be prema-
ture to abandon this field of investigation and second-
generation clinical trials of allo-based adoptive cell
therapy in less advanced patients should be pursued,
what is the next step to be taken [38]?
A first consideration to be made regarding those
patients who might be candidates to this approach.
Once feasibility has been demonstrated, patients pro-
gressing should no longer be referred for this
approach. In many hematologic malignancies a disease
that is at least stable and has a low tumor burden rep-
resents an ideal target to study reduced intensity HCT
[56]; the same rules are also valid in solid tumors. In
mCRC, patients matching these conditions are proba-
bly those who had a partial response or a stable disease
after second-line therapy. Second-generation clinical
trials of allo-based cell therapy must focus on this pop-
ulation. Together with a selection of patients, every
effort to generate safely a specific graft-versus-CRC
effect has to be pursued. The introduction of a post-
transplant vaccination as well as the infusion of
expanded tumor-specific donor lymphocytes represent
2 potential strategies that may specifically enhance the
specificity and effectiveness of allogeneic cell therapy.
It is also important to remark that in the era of molec-
ular therapies the aim of this new immunologic
approach is not to substitute available treatments but
to integrate them, to improve the response rates of
patients affected by metastatic CRC and, in the future,
hopefully achieve long-lasting remissions.ACKNOWLEDGMENTS
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